摘要
目的评估低分子肝素在高血压脑出血患者预防深静脉血栓形成的疗效及安全性。方法采用随机分组的方法，将符合条件的60例高血压脑出血患者分为低分子肝素观察组和对照组。观察组32例，入院后第1天至14天皮下连续注射低分子肝素。对照组28例，未行抗凝措施。两组患者分别于术后1d，7d和14d行双下肢静脉超声多普勒检查，评估是否发生深静脉血栓。入院后1d，7d复查头颅CT，评估是否发生颅内再出血。结果观察组32例，无一例下肢深静脉血栓形成。对照组28例，发生下肢深静脉血栓8例（28。6％），其中6例（21．4％）发生在瘫痪侧，7例（25．0％）发生在瞩静脉以下，有症状者2例（7．1％），经治疗后好转；发生症状性肺栓塞1例（3．6％）。两组发生颅内出血各1例，经积极治疗后病情均稳定。两组间再出血差异无统计学意义，肺栓塞发生率两组间差异无统计学意义，而下肢深静脉血栓形成（深静脉血栓28．6％VS0），差异有统计学意义（P〈0．01）。结论高血压脑出血患者皮下注射低分子肝素，对预防深静脉血栓形成是安全有效的。
Objective To assess the safety and availability of low molecular weight heparin （ LMWH ） for venous thromboembolism prevention in patients with hypertensive cerebral hemorrhage. Methods Sixty patients of hypertensive cerebral hemorrhage were randomly divided into 2 groups ： LMWH prophylactic group （ n=32 ） and control group （ n=28 ） . The patients in prophylactic group were injected hypodermically with LMWH from day 1 to day 14 after admission, while the patients in control group were given routine treatment. The deep vein of lower limbs in all patients were examined with color Doppler at day 1, 7, 14. CT scanning of brain were reexamined at day 1 and 7. Results In prophylactic group, no deep vein thrombosis occurred and one cerebral hemorrhage recurred. In control group, deep vein thrombosis was found in 8 cases （ 28.6% ） , and one cerebral hemorrhage recurred, and one pulmonary embolism was found. The DVT incidence between groups was significantly different, but the PTE incidence was not significantly different. Conclusion LMWH is safe and available for deep venous thromboembolism prevention in patients with hypertensive cerebral hemorrhage.
出处
《浙江临床医学》
2012年第9期1030-1032,共3页
Zhejiang Clinical Medical Journal
关键词
低分子肝素
高血压脑出血
预防性治疗
深静脉血栓
Low molecular weight heparin Hypertensive cerebral hemorrhage Prophylactic treaanent Deep vein thrombosis
